One To Watch

Theravance Biopharma

A commercial-stage biopharmaceutical company focused on respiratory disease and other specialty conditions. Theravance Biopharma develops and commercializes small-molecule medicines, combining internally discovered programs with partnerships that support global commercialization.

Company Overview

Theravance Biopharma develops therapies for respiratory and other serious diseases with unmet medical need. The company’s strategy has historically centered on organ-selective small molecules designed to deliver therapeutic activity to specific tissues while limiting systemic side effects.

Its commercial portfolio includes medicines for chronic obstructive pulmonary disease (COPD), alongside clinical programs exploring additional indications in neurology and inflammation.

Headquarters and Global Presence

Theravance Biopharma is headquartered in South San Francisco, California, United States.

The company conducts research and development in the United States and works with international partners for commercialization and clinical development activities.

Founding and History

Theravance’s origins date to 1996, when the company was founded to develop small-molecule medicines targeting respiratory disease and other conditions.

In 2014 the business separated into two companies: Theravance Biopharma, which retained the drug development pipeline, and Innoviva, which holds royalty interests in partnered respiratory medicines such as inhaled combination therapies developed with GlaxoSmithKline.

Therapy Areas and Focus

Theravance’s programs focus on several disease areas:

Respiratory diseases, particularly COPD
Neurological disorders linked to autonomic dysfunction
Inflammatory and immunological diseases

Technology Platforms and Modalities

The company develops primarily small-molecule therapies.

Key modalities include:

Long-acting muscarinic antagonists for respiratory disease
Norepinephrine reuptake inhibitors for autonomic disorders
Tissue-targeted small molecules designed to act selectively in specific organs

These programs are developed internally and, in some cases, through partnerships with larger pharmaceutical companies.

Key Products and Pipeline

Key marketed and clinical programs include:

YUPELRI (revefenacin), a nebulized long-acting muscarinic antagonist for maintenance treatment of COPD
Ampreloxetine, a norepinephrine reuptake inhibitor studied for neurogenic orthostatic hypotension associated with multiple system atrophy
Royalty interests linked to Trelegy Ellipta, an inhaled COPD and asthma therapy developed with GlaxoSmithKline

Key Personnel

Rick Winningham, Chief Executive Officer
Aziz Sawaf, Chief Financial Officer

Strategic Partnerships

Partnerships have been central to Theravance’s development model.

Key collaborations include:

Viatris, for development and commercialization of YUPELRI
GlaxoSmithKline (historically), for inhaled respiratory therapies including Trelegy Ellipta

These partnerships allow the company to leverage larger commercial infrastructures while focusing on discovery and early development.

FAQ Section

Theravance has historically combined internal drug discovery with a royalty-based partnership model. Rather than building a large commercial organization, the company has often partnered with larger pharmaceutical companies for global development and commercialization of respiratory therapies.

This structure allows the company to generate revenue from partnered products while continuing to develop internally discovered drug candidates.

The company’s early scientific work focused on respiratory pharmacology and inhaled therapies. This led to collaborations with GlaxoSmithKline that produced widely used COPD and asthma medicines, including Trelegy Ellipta.

These collaborations helped establish Theravance’s expertise in respiratory drug discovery and shaped its long-term development strategy.

YUPELRI is a nebulized long-acting bronchodilator used for maintenance treatment of COPD. It represents Theravance’s primary internally discovered product currently marketed for respiratory disease.

The therapy is commercialized through a partnership with Viatris.

Ampreloxetine was developed for neurogenic orthostatic hypotension associated with multiple system atrophy. A Phase III clinical trial did not meet its primary endpoints, prompting the company to reassess its development strategy and evaluate potential strategic options.

Developing respiratory medicines often requires large clinical trials and extensive commercialization infrastructure. Partnerships with larger pharmaceutical companies allow Theravance to advance drug programs globally without building a large commercial organization.

The pipeline includes respiratory therapies, neurological programs and research in inflammatory diseases. However, the company’s portfolio has historically been concentrated in respiratory medicine.

Key developments to watch include:

commercial performance of YUPELRI
strategic decisions following the setback in the ampreloxetine program
potential restructuring or partnerships affecting the company’s future direction.

Want to Update your Company's Profile?